Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM336 for Desensitization of Kidney Transplant Candidates
NCT07789431Phase 2Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- Oct 2026
- Primary completion
- Jul 2030
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gamgertamig in Human Leukocyte Antigen Sensitization, sponsored by Medical University of Vienna. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 24 weeks and Level of virtual panel-reactive antibody at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT07789431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789431.